Ocular Therapeutix, Inc.
OCUL
$11.87
-$0.43-3.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -18.14% | -27.59% | 15.41% | 2.28% | 8.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.14% | -27.59% | 15.41% | 2.28% | 8.26% |
| Cost of Revenue | 74.62% | 99.99% | 140.14% | 135.51% | 85.18% |
| Gross Profit | -184.14% | -358.64% | -804.21% | -1,663.50% | -1,048.93% |
| SG&A Expenses | 33.91% | 25.34% | 47.30% | 27.43% | 8.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.99% | 60.84% | 94.13% | 79.10% | 43.56% |
| Operating Income | -93.87% | -102.16% | -152.24% | -139.40% | -69.62% |
| Income Before Tax | -54.91% | 1.23% | -65.60% | -6,972.29% | -111.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.91% | 1.23% | -65.60% | -6,972.29% | -111.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.91% | 1.23% | -65.60% | -6,972.29% | -111.67% |
| EBIT | -93.87% | -102.16% | -152.24% | -139.40% | -69.62% |
| EBITDA | -96.31% | -105.02% | -159.92% | -145.79% | -70.37% |
| EPS Basic | -48.83% | 23.03% | 16.79% | -3,261.54% | 0.38% |
| Normalized Basic EPS | -85.85% | -35.26% | 16.78% | -17.96% | 20.17% |
| EPS Diluted | -48.83% | 22.64% | 16.79% | 13.15% | 0.38% |
| Normalized Diluted EPS | -85.85% | -35.26% | 16.78% | -26.48% | 20.17% |
| Average Basic Shares Outstanding | 4.08% | 28.31% | 99.00% | 110.39% | 112.47% |
| Average Diluted Shares Outstanding | 4.08% | 28.31% | 99.00% | 96.13% | 112.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |